Trial Outcomes & Findings for A Study of Modified Stem Cells in Stable Ischemic Stroke (NCT NCT01287936)

NCT ID: NCT01287936

Last Updated: 2023-02-03

Results Overview

Number of subjects with TEAEs by maximum severity. The severity of all AEs was assessed by the Investigator using the World Health Organization (WHO) Toxicity Scale. For abnormalities not found elsewhere in the WHO table, the following scale was used to assign severity: Mild: Transient mild discomfort; no limitation in activity; no medical intervention/therapy required. Moderate: Mild-to-moderate limitation in activity; some assistance may be need. No or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required; hospitalization or prolongation of current hospitalization possible. Life-threatening: Extreme limitation in activity, significant assistance required; significant medial intervention/therapy required; hospitalization or prolongation of current hospitalization or hospice care probable.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

18 participants

Primary outcome timeframe

6 months

Results posted on

2023-02-03

Participant Flow

Participant milestones

Participant milestones
Measure
SB623 Implant (2.5M)
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
10 million SB623 cells SB623: SB623, a modified stem-cell product
Overall Study
STARTED
6
6
6
Overall Study
COMPLETED
6
5
5
Overall Study
NOT COMPLETED
0
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
SB623 Implant (2.5M)
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
10 million SB623 cells SB623: SB623, a modified stem-cell product
Overall Study
Lost to Follow-up
0
1
1

Baseline Characteristics

A Study of Modified Stem Cells in Stable Ischemic Stroke

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Total
n=18 Participants
Total of all reporting groups
Age, Continuous
60.0 years
STANDARD_DEVIATION 7.62 • n=99 Participants
67.2 years
STANDARD_DEVIATION 7.60 • n=107 Participants
56.8 years
STANDARD_DEVIATION 13.30 • n=206 Participants
61.3 years
STANDARD_DEVIATION 10.29 • n=7 Participants
Sex: Female, Male
Female
3 Participants
n=99 Participants
4 Participants
n=107 Participants
4 Participants
n=206 Participants
11 Participants
n=7 Participants
Sex: Female, Male
Male
3 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
7 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
n=99 Participants
6 Participants
n=107 Participants
6 Participants
n=206 Participants
18 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Asian
2 Participants
n=99 Participants
2 Participants
n=107 Participants
1 Participants
n=206 Participants
5 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
White
3 Participants
n=99 Participants
4 Participants
n=107 Participants
5 Participants
n=206 Participants
12 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Region of Enrollment
United States
6 participants
n=99 Participants
6 participants
n=107 Participants
6 participants
n=206 Participants
18 participants
n=7 Participants

PRIMARY outcome

Timeframe: 6 months

Population: Safety population includes all enrolled patients who have received study treatment and who have any post-baseline data.

Number of subjects with TEAEs by maximum severity. The severity of all AEs was assessed by the Investigator using the World Health Organization (WHO) Toxicity Scale. For abnormalities not found elsewhere in the WHO table, the following scale was used to assign severity: Mild: Transient mild discomfort; no limitation in activity; no medical intervention/therapy required. Moderate: Mild-to-moderate limitation in activity; some assistance may be need. No or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required; hospitalization or prolongation of current hospitalization possible. Life-threatening: Extreme limitation in activity, significant assistance required; significant medial intervention/therapy required; hospitalization or prolongation of current hospitalization or hospice care probable.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Mild
1 Participants
1 Participants
0 Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Moderate
3 Participants
2 Participants
4 Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Severe
1 Participants
3 Participants
2 Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Life threatening
1 Participants
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The ESS is the sum of 14 items that are used to assess a patient who has recently had a stroke. These 14 items are level of consciousness, comprehension, speech, visual field, gaze, facial movement, arm in outstretched position, arm raising, extension of the wrist, fingers, leg maintained in position, leg flexing, dorsiflexion of the foot, and gait. A certain number of points are given for each parameter. The range of the total score of ESS is 0 - 100, with a completely normal person having a score of 100 and maximally affected person with a score of zero.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the European Stroke Scale (ESS) Total Score From Baseline at Month 6
7.67 Change in score on a scale from baseline
Standard Deviation 8.140
4.50 Change in score on a scale from baseline
Standard Deviation 5.244
7.75 Change in score on a scale from baseline
Standard Deviation 10.012

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The ESS motor function score is a sum of the selected items: facial movement, arm in outstretched position, arm raising, extension of wrist, fingers, leg maintained in position, leg flexing, dorsiflexion of foot, and gait. A completely normal person will have a score of 66. The maximally affected person will have a score of zero.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the European Stroke Scale (ESS) Motor Function Total Score From Baseline at Month 6
6.33 Change in score on a scale from baseline
Standard Deviation 6.186
3.67 Change in score on a scale from baseline
Standard Deviation 3.933
6.25 Change in score on a scale from baseline
Standard Deviation 5.560

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The NIHSS is a standardized method used to measure the level of impairment caused by a stroke. The scale consists of 11 items that measure several aspects of brain function, including consciousness, vision, sensation, movement, speech, and language. A certain number of points are given for each impairment uncovered during a focused neurological examination. A maximal score of 42 represents the most severe and devastating stroke with 0=no stroke, 1-4=minor stroke, 5-15=moderate stroke, 15-20=moderate/severe stroke, and 21-42=severe stroke.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the National Institutes of Health Stroke Scale (NIHSS) Total Score From Baseline at Month 6
-2.00 change in score on a scale from baseline
Standard Deviation 1.265
-0.83 change in score on a scale from baseline
Standard Deviation 1.472
-2.50 change in score on a scale from baseline
Standard Deviation 3.512

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The NIHSS is a standardized method used to measure the level of impairment caused by a stroke. The NIHSS Motor Function Total Score consists of 3 items: motor arm, motor leg, and limb ataxia, with 0 = no stroke and a maximal score of 18 = most severe impairment for motor function.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the National Institutes of Health Stroke Scale (NIHSS) Motor Function Total Score From Baseline at Month 6
-1.33 change in score on a scale from baseline
Standard Deviation 0.816
-0.83 change in score on a scale from baseline
Standard Deviation 1.472
-1.00 change in score on a scale from baseline
Standard Deviation 1.414

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The mRS is a commonly used scale for measuring the degree of disability in daily activities for patients who have suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the Modified Rankin Scale (mRS) Response From Baseline at Month 6
0 Change in score on a scale from baseline
Standard Deviation 0
-0.17 Change in score on a scale from baseline
Standard Deviation 0.408
-0.25 Change in score on a scale from baseline
Standard Deviation 0.500

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The Fugl-Meyer Scale is a stroke-specific, performance-based impairment index. The scale is comprised of 5 domains (motor score, sensation, balance, joint range of motion, and joint pain) with 155 items in total. Scoring is based on direct observation of performance. Scale items in all 5 domains are scored on the basis of ability to complete the item using a 3-point Likert-type ordinal scale, where 0=cannot perform, 1=performs partially, and 2=performs fully. Points are divided among the domains: (a) Motor performance \[0 (hemiplegia) - 100 (normal motor performance) points\]; (b) Balance \[0-14 points: 6 for sitting; 8 for standing\]; (c) Sensation \[0-24 points: 8 for light touch; 16 for position sense\]; (d) Joint range of motion \[0-44 points\]; (e) Joint pain \[0-44 points\]. For all domains, a maximally affected person will score 0 while a fully functional person will have the highest score. All items are summed to provide a minimum score of 0 and a maximum score of 226.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the Fugl-Meyer Total Score From Baseline at Month 6
18.33 Change in score on a scale from baseline
Standard Deviation 13.721
17.70 Change in score on a scale from baseline
Standard Deviation 7.589
23.75 Change in score on a scale from baseline
Standard Deviation 21.975

SECONDARY outcome

Timeframe: 6 months

Population: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).

The FMMS is used as a clinical measure of body function impairment after stroke that assesses several dimensions of motor impairment, including range of motion in upper and lower limbs, reflex activity, volitional movement, and coordination. The FMMS motor total score ranged from 0 (hemiplegia) to a maximum of 100 points (normal motor performance), and is comprised of a 33-item upper extremity subscale (UE-FMMS) and the 17-item lower extremity subscale (LE-FMMS). Items were scored on a 3-point ordinal scale: 0= cannot perform; 1= partial motion; 2= full motion Individual items are summed to determine scores for the 2 subscale scores, as well as a motor total score (total of the 2 subscales UE-FMMS and LE-FMMS). As a result, the UE-FMMS subscale score ranged from 0 to 66 and the LE-FMMS subscale score ranged from 0 to 34. A maximally affected person will have a score of 0 while a fully functional person will have the highest score (i.e., 34 for LE-FMMS, 66 for UE-FMMS, 100 for FMMS)

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the Fugl-Meyer Motor Total Score (FMMS) Total Score From Baseline at Month 6
8.17 Change in score on a scale from baseline
Standard Deviation 10.834
8.67 Change in score on a scale from baseline
Standard Deviation 4.633
17.50 Change in score on a scale from baseline
Standard Deviation 20.339

SECONDARY outcome

Timeframe: 6 months

The Fugl-Meyer Upper Extremity subscale (UE-FMMS) is comprised of 33 items that assess several dimensions of motor impairment, including range of motion in upper limbs, reflex activity, volitional movement, and coordination. Scoring is based on direct observation of performance and is scored using a 3-point ordinal scale, where 0=cannot perform; 1=partial motion; and 2=full motion Individual items are summed to provide ranging from 0 (minimum) to 66 (maximum). A maximally affected person will have a score of 0 while a fully functional person will a score of 66.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the Fugl-Meyer Upper Extremity Motor Function Total Score From Baseline at Month 6
4.00 Change in score on a scale from baseline
Standard Deviation 7.321
4.50 Change in score on a scale from baseline
Standard Deviation 3.017
11.25 Change in score on a scale from baseline
Standard Deviation 15.370

SECONDARY outcome

Timeframe: 6 months

The Fugl-Meyer Lower Extremity subscale (LE-FMMS) is comprised of 17 items that assess several dimensions of motor impairment, including range of motion in lower limbs, reflex activity, volitional movement, and coordination. Scoring is based on direct observation of performance and is scored using a 3-point ordinal scale, where 0=cannot perform; 1=partial motion; and 2=full motion Individual items are summed to provide ranging from 0 (minimum) to 34 (maximum). A maximally affected person will have a score of 0 while a fully functional person will a score of 34.

Outcome measures

Outcome measures
Measure
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells SB623: SB623, a modified stem-cell product
Change in the Fugl-Meyer Lower Extremity Motor Function Total Score From Baseline at Month 6
4.17 Change in score on a scale from baseline
Standard Deviation 4.355
4.17 Change in score on a scale from baseline
Standard Deviation 3.061
6.25 Change in score on a scale from baseline
Standard Deviation 5.315

Adverse Events

SB623 Implant (2.5M)

Serious events: 2 serious events
Other events: 6 other events
Deaths: 0 deaths

SB623 Implant (5.0M)

Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths

SB623 Implant (10.0M)

Serious events: 2 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
SB623 Implant (2.5M)
n=6 participants at risk
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 participants at risk
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 participants at risk
10 million SB623 cells SB623: SB623, a modified stem-cell product
Nervous system disorders
Carotid artery stenosis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Convulsion
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Hypoaesthesia
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Transient ischaemic attack
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Infections and infestations
Pneumonia
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Infections and infestations
Sepsis
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Infections and infestations
Urinary tract infection
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Gastrointestinal disorders
Dysphagia
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months

Other adverse events

Other adverse events
Measure
SB623 Implant (2.5M)
n=6 participants at risk
2.5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (5.0M)
n=6 participants at risk
5 million SB623 cells SB623: SB623, a modified stem-cell product
SB623 Implant (10.0M)
n=6 participants at risk
10 million SB623 cells SB623: SB623, a modified stem-cell product
Nervous system disorders
Headache
66.7%
4/6 • 6 months
66.7%
4/6 • 6 months
50.0%
3/6 • 6 months
Nervous system disorders
Muscle spasticity
33.3%
2/6 • 6 months
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
Nervous system disorders
Convulsion
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Dizziness
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Hypoaesthesia
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Pneumocephalus
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Carotid artery stenosis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Muscle contractions involuntary
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Myoclonus
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Presyncope
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Pseudobulbar palsy
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Subdural hygroma
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Transient ischaemic attack
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Nervous system disorders
Unresponsive to stimuli
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Injury, poisoning and procedural complications
Procedural headache
33.3%
2/6 • 6 months
0.00%
0/6 • 6 months
50.0%
3/6 • 6 months
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Extradural haematoma
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Injury, poisoning and procedural complications
Incision site erythema
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Incision site pain
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Postoperative fever
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Wound
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Injury, poisoning and procedural complications
Wound complication
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Gastrointestinal disorders
Nausea
0.00%
0/6 • 6 months
50.0%
3/6 • 6 months
50.0%
3/6 • 6 months
Gastrointestinal disorders
Vomiting
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
33.3%
2/6 • 6 months
Gastrointestinal disorders
Constipation
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
16.7%
1/6 • 6 months
Gastrointestinal disorders
Diarrhoea
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
Gastrointestinal disorders
Dysphagia
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
Gastrointestinal disorders
Gastrooesophageal reflux disease
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Gastrointestinal disorders
Proctalgia
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Gastrointestinal disorders
Tooth loss
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Musculoskeletal and connective tissue disorders
Pain in extremity
33.3%
2/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Arthralgia
33.3%
2/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Muscle spasms
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Back pain
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Joint swelling
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Mobility decreased
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Neck pain
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Musculoskeletal and connective tissue disorders
Tendonitis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
General disorders
Fatigue
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
33.3%
2/6 • 6 months
General disorders
Gait disturbance
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
General disorders
Influenza like illness
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
General disorders
Neurological complication associated with device
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
General disorders
Pain
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
General disorders
Pyrexia
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
General disorders
Vessel puncture site bruise
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Infections and infestations
Urinary tract infection
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
Infections and infestations
Pneumonia
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
Infections and infestations
Candidiasis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Infections and infestations
Cystitis
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Infections and infestations
Diverticulitis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Infections and infestations
Nasopharyngitis
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Infections and infestations
Sepsis
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Infections and infestations
Upper respiratory tract infection
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Infections and infestations
Vulvovaginal mycotic infection
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Blood glucose increased
33.3%
2/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
C-reactive protein increased
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
16.7%
1/6 • 6 months
Investigations
Alanine aminotransferase increased
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Aspartate aminotransferase increased
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Blood alkaline phosphatase increased
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Investigations
Blood magnesium decreased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Blood pressure increased
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Blood triglycerides increased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Lipids increased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Low density lipoprotein increased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Lymphocyte count decreased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Non-high-density lipoprotein cholesterol increased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Investigations
Weight increased
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Respiratory, thoracic and mediastinal disorders
Nasal congestion
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Respiratory, thoracic and mediastinal disorders
Wheezing
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Blood and lymphatic system disorders
Anaemia
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Blood and lymphatic system disorders
Lymphadenopathy
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Blood and lymphatic system disorders
Neutropenia
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Psychiatric disorders
Depression
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
33.3%
2/6 • 6 months
Psychiatric disorders
Confusional state
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Psychiatric disorders
Dissociation
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Psychiatric disorders
Emotional distress
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Psychiatric disorders
Panic attack
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Metabolism and nutrition disorders
Decreased appetite
0.00%
0/6 • 6 months
33.3%
2/6 • 6 months
0.00%
0/6 • 6 months
Skin and subcutaneous tissue disorders
Skin discolouration
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Skin and subcutaneous tissue disorders
Urticaria
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Vascular disorders
Hypertension
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Vascular disorders
Hypotension
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
Ear and labyrinth disorders
Tinnitus
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
16.7%
1/6 • 6 months
Renal and urinary disorders
Urinary incontinence
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months
Reproductive system and breast disorders
Prostatomegaly
16.7%
1/6 • 6 months
0.00%
0/6 • 6 months
0.00%
0/6 • 6 months

Additional Information

Bijan Nejadnik M.D.; Chief Medical Officer

SanBio, Inc.

Phone: 650-625-2205

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place